Geode Capital Management
ARCT icon

Geode Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Geode Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Buy
693,660
+32,732
+5% +$258K ﹤0.01% 2955
2026
Q1 		$5.1M Buy
660,928
+42,794
+7% +$312K ﹤0.01% 2725
2025
Q4 		$3.79M Buy
618,134
+6,311
+1% +$68.2K ﹤0.01% 2914
2025
Q3 		$11.3M Buy
611,823
+5,532
+0.9% +$88.9K ﹤0.01% 2353
2025
Q2 		$7.89M Buy
606,291
+36,671
+6% +$434K ﹤0.01% 2498
2025
Q1 		$6.03M Buy
569,620
+14,636
+3% +$232K ﹤0.01% 2570
2024
Q4 		$9.42M Buy
554,984
+3,186
+0.6% +$60K ﹤0.01% 2416
2024
Q3 		$12.8M Buy
551,798
+5,789
+1% +$124K ﹤0.01% 2229
2024
Q2 		$13.3M Sell
546,009
-4,254
-0.8% -$129K ﹤0.01% 2154
2024
Q1 		$18.6M Buy
550,263
+11,998
+2% +$425K ﹤0.01% 1965
2023
Q4 		$17M Buy
538,265
+26,097
+5% +$620K ﹤0.01% 2013
2023
Q3 		$13.1M Buy
512,168
+16,992
+3% +$523K ﹤0.01% 2093
2023
Q2 		$14.2M Buy
495,176
+27,060
+6% +$737K ﹤0.01% 2078
2023
Q1 		$11.2M Buy
468,116
+18,177
+4% +$326K ﹤0.01% 2191
2022
Q4 		$7.63M Buy
449,939
+33,148
+8% +$578K ﹤0.01% 2436
2022
Q3 		$6.18M Buy
416,791
+24,254
+6% +$407K ﹤0.01% 2556
2022
Q2 		$6.18M Buy
392,537
+21,554
+6% +$423K ﹤0.01% 2579
2022
Q1 		$10M Sell
370,983
-4,130
-1% -$105K ﹤0.01% 2343
2021
Q4 		$13.9M Sell
375,113
-25,256
-6% -$1.03M ﹤0.01% 2217
2021
Q3 		$19.1M Buy
400,369
+16,752
+4% +$751K ﹤0.01% 1986
2021
Q2 		$13M Buy
383,617
+27,721
+8% +$938K ﹤0.01% 2281
2021
Q1 		$14.7M Buy
355,896
+31,500
+10% +$1.88M ﹤0.01% 2081
2020
Q4 		$14.1M Buy
324,396
+54,862
+20% +$3.72M ﹤0.01% 1930
2020
Q3 		$11.6M Buy
269,534
+57,333
+27% +$2.85M ﹤0.01% 1857
2020
Q2 		$9.92M Buy
212,201
+123,714
+140% +$4.26M ﹤0.01% 1924
2020
Q1 		$1.2M Buy
88,487
+3,992
+5% +$51.1K ﹤0.01% 2933
2019
Q4 		$918K Buy
84,495
+5,745
+7% +$60.1K ﹤0.01% 3307
2019
Q3 		$808K Buy
78,750
+65,277
+485% +$706K ﹤0.01% 3306
2019
Q2 		$127K Buy
+13,473
New +$98.9K ﹤0.01% 3902
2017
Q4 		– Sell
-1,576
Closed -$11K – 4025
2017
Q3 		$11K Hold
1,576
– – ﹤0.01% 4036
2017
Q2 		$12K Sell
1,576
-673
-30% -$5.42K ﹤0.01% 4069
2017
Q1 		$17K Buy
2,249
+92
+4% +$852 ﹤0.01% 4048
2016
Q4 		$31K Buy
2,157
+61
+3% +$912 ﹤0.01% 3971
2016
Q3 		$36K Buy
2,096
+15
+0.7% +$485 ﹤0.01% 3947
2016
Q2 		$65K Hold
2,081
– – ﹤0.01% 3883
2016
Q1 		$55K Buy
+2,081
New +$70.5K ﹤0.01% 3954

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management's ARCT Position: Q2 2026 in Review

Geode Capital Management increased its Arcturus Therapeutics (ARCT) stake by 5% in Q2 2026, buying an estimated $258K and bringing the position to 693,660 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2955.

Geode Capital Management first reported a position in ARCT in Q1 2016 and has held it in 36 quarters since. The position peaked at $19.1M in Q3 2021. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Geode Capital Management held 693,660 shares of Arcturus Therapeutics worth $4.66M as of Q2 2026.
  • Geode Capital Management bought 32,732 Arcturus Therapeutics shares in Q2 2026, an estimated $258K.
  • Arcturus Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2955 holding.
  • Geode Capital Management first reported a position in Arcturus Therapeutics in Q1 2016 and has held it in 36 quarters since.
  • Geode Capital Management's Arcturus Therapeutics position peaked at $19.1M in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.